College of Pharmacy Faculty Research ​and Publications

New Drug: Tirzepatide (Mounjaro™)

Document Type

Article

Publication Title

The Senior Care Pharmacist

Publication Date

2-1-2023

Volume

38

Issue

2

First Page

50

Last Page

62

Abstract

Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a chronic and progressive illness. Millions of Americans have T2DM and many patients do not achieve the recommended blood glucose levels. Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment for the management of T2DM and is recommended early in the treatment algorithm. GLP-1 therapy is associated with better glycemic control, weight reduction, and favorable cardiovascular outcomes. Tirzepatide (Mounjaro™) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist. Evidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to GLP-1 receptor agonists. This paper gives an overview of tirzepatide and SURPASS clinical trials.

Copyright held by

American Society of Consultant Pharmacists

Link to Full Text

Share

COinS